2025-05-02 10:08:52
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Strides Pharma Science Ltd Q4 FY23 consolidated loss at Rs. 9.54 crores
Posted On : 2023-05-25 15:13:28( TIMEZONE : IST )
Strides Pharma Science Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 1013.491 crores during the period ended March 31, 2023 as compared to Rs. 891.046 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. -9.542 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. -80.026 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. -1.06 for the period ended March 31, 2023 as compared to Rs. -8.86 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹1013.491 crs | ₹891.046 crs |  13.74% |
| Net Profit | ₹-9.542 crs | ₹-80.026 crs |  88.08% |
| EPS | ₹-1.06 | ₹-8.86 | 88.04% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.1013.491 crores during the period ended March 31, 2023 as compared to Rs.952.075 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.-9.542 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.29.219 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.-1.06 for the period ended March 31, 2023 as compared to Rs.3.25 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹1013.491 crs | ₹952.075 crs | 6.45% |
| Net Profit | ₹-9.542 crs | ₹29.219 crs |  -132.66% |
| EPS | ₹-1.06 | ₹3.25 | -132.62% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.3778.715 crores during the Financial Year ended March 31, 2023 as compared to Rs.3202.238 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.-202.635 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.-460.211 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.-22.49 for the Financial Year ended March 31, 2023 as compared to Rs.-51.28 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹3778.715 crs | ₹3202.238 crs | 18.00% |
| Net Profit | ₹-202.635 crs | ₹-460.211 crs | 55.97% |
| EPS | ₹-22.49 | ₹-51.28 | 56.14% |
Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 377.60 as compared to the previous close of Rs. 368.90. The total number of shares traded during the day was 36465 in over 1564 trades.
The stock hit an intraday high of Rs. 379.80 and intraday low of 365.05. The net turnover during the day was Rs. 13715945.00.
